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Abstract
Introduction
The larynx is a part of the upper respiratory tract that performs many essential functions
including breathing, speaking, and swallowing. For this reason, the quality of life is
significantly affected by laryngeal cancer and its treatment. Therefore, the focus of
management for the last few decades has been on preserving the function of a larynx without
compromising survival. This study was done with the purpose of reviewing our experience of
organ preservation approach with concurrent chemoradiation therapy (CCRT) for locally
advanced cancers of larynx.
Methods
A retrospective chart review was carried out for the data of pathology reports and clinical notes
of the patients who were diagnosed with laryngeal squamous cell carcinoma and primarily
treated with CCRT at our tertiary care institute from November 2010 to June 2015.
Results
Of 25 patients included in the study, there were 19 males and six females. The mean age was 56
years. On comparison of post-treatment CT scan following eight weeks of completion of
therapy, 21 patients showed complete resolution of the disease and four patients had persistent
disease who were later treated with salvage laryngectomy. The speech was understandable in
18 patients and poor or not understandable in seven patients. Three patients had chronic
aspiration and breathing difficulties necessitating permanent tracheostomy. Three patients
required permanent gastrostomy due to chronic dysphagia, one of them belonged to those who
were also tracheostomized.
Conclusions
Our experience with CCRT as an organ preservation approach for advanced laryngeal
cancers was promising. When considering the functional organ preservation, the proportion of
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success is remarkably less; however, the overall impression is worthy enough to uphold the
sentiment in favor of non-surgical organ preservation. The debate is ongoing in the quest of
finding a balanced approach with acceptable toxicity and decent functional outcome with
adequate speech, breathing, and swallowing.
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Introduction
Cancer is one of the leading causes of death and forms the single most important barrier to
improve life expectancy worldwide in the era of modern medicine [1]. The reasons for rapidly
growing cancer incidence and mortality are complex and probably reflect the increasing world
population and aging. Decline in mortality rates of stroke and ischemic heart disease also
partly responsible for this phenomenon of cancer emerging as a leading cause of death in many
countries [2,3]. This transition seems to be more dramatic in developing countries [1].
The larynx is a part of the upper respiratory tract that performs many essential functions
including breathing, speaking, and swallowing. For this reason, the quality of life is
significantly affected by laryngeal cancer and its treatment. Therefore, the focus of
management for the last few decades has been on preserving the function of the larynx without
compromising survival [4]. 
The three landmark studies published in 1991, 1996, and 2003 investigated and evaluated
locally advanced laryngeal and hypopharyngeal cancers [5-7]. In 2006, a multidisciplinary
expert panel reviewed the literature available through 2005 and the results of these landmark
studies led to the development of clinical practice guidelines for the use of larynx-preservation
strategies by the American Society of Clinical Oncology (ASCO). ASCO concluded the review
with the following recommendations: “All patients with T1 or T2 laryngeal cancer, with rare
exception, should be treated initially with intent to preserve the larynx. For most patients with
T3 or T4 disease without tumor invasion through cartilage into soft tissues, a larynx-
preservation approach is an appropriate, standard treatment option, and concurrent
chemoradiation therapy is the most widely applicable approach. To ensure an optimum
outcome, special expertise and a multidisciplinary team are necessary, and the team should
fully discuss with the patient the advantages and disadvantages of larynx-preservation options
compared with treatments that include total laryngectomy” [8].
These guidelines published by ASCO in 2006 form the basis of the current standard of practice
in the treatment of laryngeal cancer to avoid total laryngectomy as the preferred treatment
option. This has been reconfirmed in the number of recent reviews [9-12]. Total laryngectomy is
generally recognized as one of the radical and mutilating surgical procedures most dreaded by
patients. Common consequences following total laryngectomy include social isolation, job loss,
and depression [8]. Although the non-surgical management has largely replaced surgery for a
selected group of advanced laryngeal carcinoma, there still remains an important role of
surgery, in particular, total laryngectomy in cases of advanced extra laryngeal and recurrent
disease [13]. This study was done with the purpose of reviewing our experience of the organ
preservation approach with concurrent chemoradiation therapy (CCRT) for locally advanced
cancers of larynx.
Materials And Methods
Institutional ethical approval was obtained before starting the study. A retrospective chart
review was carried out for the data of pathology reports and clinical notes of the patients who
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were diagnosed with laryngeal squamous cell carcinoma and primarily treated with CCRT at our
tertiary care institute from November 2010 to June 2015.
Patients with a history of previous treatment including surgery, radiotherapy, and
chemotherapy were all excluded. A total of 25 patients were included in the study with the
diagnosis of locally advanced laryngeal carcinoma. These patients were offered chemoradiation
therapy as a protocol for organ preservation being in practice during the given period at the
institute after full discussion with the patient and the family about the pros and cons of larynx
preservation versus total laryngectomy.
The staging was done according to the seventh edition of the AJCC (American Joint
Commission on Cancer) [14]. Larynx and upper neck were treated with 2.0 Gy per fraction, once
a day, for five days a week to a total dose of 70 Gy in 35 fractions over a period of seven weeks.
Concurrent chemotherapy with cisplatin or carboplatin was given as a three-weekly schedule
(days 1, 22, 43).
Treatment response was assessed by comparison of pre- and post-treatment CT scans with
contrast. Post-treatment CT scan with contrast was done after eight weeks of completion of
therapy. The functional outcome of larynx preservation was assessed for the speech, need of
gastrostomy tube, and tracheostomy tube. Statistical package for social sciences version 18
(SPSS Inc., Chicago, IL) was used for statistical analysis.
Results
Of 25 patients included in the study, there were 19 males and six females. The mean age was 56
years. All the patients had stage III disease. The tumor was limited to the larynx in 23 patients






Mean age 56 years
Age range 46-72 years
Disease extent
Stage III, limited to larynx 23
Stage III, pyriform fossa involved 2
TABLE 1: Gender, age, and staging
Histologically, 12 of 25 patients had grade I, nine had grade II and four had grade III tumors as
shown in Table 2.
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Tumor grade Histology Number of patients
Grade I Well differentiated SCC 12
Grade II Moderately differentiated SCC 9
Grade III Poorly differentiated SCC 4
TABLE 2: Histological grading of tumors
SCC: squamous cell carcinoma
On comparison of post-treatment CT scan following eight weeks of completion of therapy, 21
patients showed complete resolution of the disease and four patients had persistent disease
who were later treated with salvage laryngectomy. Treatment response to CCRT is shown in
Table 3.
Treatment response Number of patients
Complete resolution 21
Persistent disease 4
TABLE 3: Treatment response to concurrent chemoradiation therapy
The speech was understandable in 18 patients and poor or not understandable in seven
patients. Three patients had chronic aspiration and breathing difficulties necessitating
permanent tracheostomy. Three patients required permanent gastrostomy due to chronic
dysphagia, one of them belonged to those who were also tracheostomized. The total number of
organs preserved was 21 (84%); however, nine organs were preserved with good function (36%).
Organ and function preservation is shown in Table 4.
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Able to swallow 22
Gastrostomy dependent 3
Organ preservation
Total  organs preserved 21
Organ preservation with good function 9
TABLE 4: Organ and function preservation
Discussion
The study on patient preference for longevity and voice preservation in 1981 revealed that 20%
of the study population were willing to accept 20% to 30% less survival by opting for
radiotherapy instead of total laryngectomy. This attitude was due to the fact that
radiation therapy (RT) preserves normal or nearly normal speech [15]. However, the subjects in
the study were all healthy individuals and their attitude may not be a true reflection of the
feelings and emotions of a genuine patient.
The landmark publication by Veterans Affairs (VA) Laryngeal Cancer Study Group reported that
the efficacy of chemotherapy followed by radiotherapy was similar to that of surgery followed
by radiotherapy and offered the added benefit of laryngeal preservation in two-thirds of the
patients treated by this approach [5]. However, in this study, organ preservation was
interpreted more like an “organ in place” regardless of its functional capability.
Subsequently, Forastiere et al. (RTOG 91-11 trial) reported a randomized trial in which
induction chemotherapy followed by radiotherapy was compared with two other regimens:
concurrent chemoradiation therapy in one group and radiation therapy alone in another group
of patients. The trial confirmed that the outcome in patients who were able to tolerate
chemotherapy was best with CCRT [7]. However, there was no difference in overall survival
amongst patients treated with other regimens. Similar to the study by VA, this trial was also
lacking the reporting of laryngeal functions (swallowing, speaking, and breathing) which is
necessary for a practical interpretation of the outcome.
The main disadvantage of organ preservation by CRT is the persistence of disease after
completion of treatment or early relapse after curative treatment requiring salvage surgery [16].
Most of the surgeons worldwide accept salvage total laryngectomy as a suitable option after
failure or recurrence for patients treated with organ preservation protocol. However, these
patients are more prone to develop a number of complications as compared to those who were
treated primarily with surgery [17-22].
The authors of the globally most noticeable RTOG 91-11 trial reported their long-term results
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in 2013 and essentially maintained their initial recommendations and concluded that 10-year
results of induction chemotherapy followed by RT and CCRT were similar in efficacy for the
laryngectomy-free survival (LFS) endpoint. However, locoregional control and larynx
preservation were significantly improved with CCRT compared with the induction arm or RT
alone. They recommended that new strategies to improve organ preservation and function with
less morbidity are needed [23]. The CCRT offers a significantly higher chance of larynx
preservation than RT alone or induction chemotherapy followed by RT, albeit at the cost of more
acute toxicities and no improvement in overall survival [16]. Moreover, the CCRT arm showed
lower compliance and a much higher rate of “late death unrelated to cancer” (36% in the CCRT
arm vs. 18% in both comparator arms, RT or IC+RT) [16]. 
Lately, the German multicenter randomized phase II trial for larynx preservation for locally
advanced laryngeal/hypopharyngeal cancer was published in the official journal of the
European Society for Medical Oncology. The purpose of the study was to test the hypothesis
that the addition of cetuximab to induction chemotherapy (IC) and radiotherapy improves LFS.
Response to first IC cycle (IC-1) with >30% endoscopically estimated tumor surface shrinkage
was used to define early responders; early salvage TL was recommended to non-responders
[24]. This empirical endoscopically assessed cut-off of >30% was introduced the first time in
literature. The primary objective of 24-month LFS of >35% was achieved in both arms of the
study, 46.6% in arm A and 45.4% in arm B.
The endoscopic assessment of tumor is one of the routine ENT (ear, nose and throat)
procedures and certainly provides a high level of assessment due to direct visualization than
the comparison on imaging studies which likely be misleading in the first week of therapy.
Consequently, non-responders can undergo early salvage total laryngectomy before completing
the full course and therefore avoid higher toxicity of CCRT and complication rate of traditional
late salvage laryngectomy.
Conclusions
Our experience with CCRT as an organ preservation approach for advanced laryngeal
cancers was promising. When considering the functional organ preservation, the proportion of
success is remarkably less; however, the overall impression is worthy enough to uphold the
sentiment in favor of non-surgical organ preservation. The debate is ongoing in the quest of
finding a balanced approach with acceptable toxicity and decent functional outcome with
adequate speech, breathing, and swallowing.
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